Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has issued an update.
Shanghai Fosun Pharmaceutical announced that its subsidiary, Jinzhou Avanc Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the drug registration of Fovinaciclib Citrate Capsules. This drug is indicated for the treatment of adult patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer, in combination with an aromatase inhibitor as initial endocrine therapy. This approval is expected to enhance the company’s product offerings in the oncology sector and strengthen its position in the pharmaceutical market.
The most recent analyst rating on (HK:2196) stock is a Hold with a HK$17.20 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, focusing on the pharmaceutical industry. The company is involved in the development, manufacture, and sale of pharmaceutical products, with a market focus on innovative drugs and treatments.
YTD Price Performance: 96.84%
Average Trading Volume: 11,114,885
Technical Sentiment Signal: Buy
Current Market Cap: HK$87.96B
Learn more about 2196 stock on TipRanks’ Stock Analysis page.